Abstract
Chronic nitric oxide inhibition promotes hypertension, renal dysfunction, and renal injury by unclear mechanisms. We examined the effects in this model of concomitant treatment with the calcium channel blocker nifedipine. Six adult male Munich-Wistar rats received 0.025% nifedipine in chow. Six untreated rats served as controls. Fifteen days later, renal function was evaluated in anesthetized rats before and after a bolus injection of the nitric oxide inhibitor N omega-nitro-L-arginine methyl ester at 3 mg/kg IV. Renal vasoconstriction and systemic hypertension induced by the inhibitor were similar in untreated and nifedipine-treated rats. In a second protocol, eight rats received the nitric oxide inhibitor in their drinking water at 2.6 mmol/L. Eight additional rats also received nifedipine as above. At day 15, rats given the nitric oxide inhibitor exhibited systemic hypertension and renal vasoconstriction. Simultaneous nifedipine lowered blood pressure slightly without ameliorating renal hemodynamics. Tail-cuff pressure rose continuously in rats receiving the nitric oxide blocker, reaching 171 +/- 7 mm Hg at 30 days, but remained at 143 +/- 3 mm Hg in rats also given nifedipine. At this stage, rats treated with the nitric oxi...Continue Reading
References
Aug 23, 1979·Virchows Archiv. A, Pathological Anatomy and Histology·F L Jepsen, P B Mortensen
Oct 1, 1992·Hypertension·R Correa-RotterM E Rosenberg
Sep 1, 1992·Hypertension·M O RibeiroR Zatz
Feb 25, 1992·European Journal of Pharmacology·E WöllF Lang
Jul 1, 1992·The Journal of Clinical Investigation·C BaylisA Deng
Aug 31, 1990·Biochemical and Biophysical Research Communications·U C Garg, A Hassid
May 1, 1991·The American Journal of Physiology·K IijimaM S Goligorsky
Jul 1, 1990·Kidney International·A K BidaniE J Lewis
Jan 1, 1989·The Journal of Clinical Investigation·K F BadrR C Harris
Apr 1, 1989·The Biochemical Journal·T J HallamJ E Merritt
Jun 1, 1989·The American Journal of Physiology·P K Carmines, L G Navar
Oct 1, 1989·The American Journal of Physiology·R LoutzenhiserM Epstein
Jun 1, 1986·The Journal of Clinical Investigation·S AndersonB M Brenner
Oct 1, 1969·The Journal of Clinical Endocrinology and Metabolism·E HaberA Purnode
Jul 1, 1980·Circulation Research·S WallensteinJ L Fleiss
May 1, 1994·Journal of Cardiovascular Pharmacology·N NafrialdiA Mimran
Jan 1, 1995·Journal of the American Society of Nephrology : JASN·C K FujiharaR Zatz
Jul 1, 1994·Kidney International·P MenèG A Cinotti
Sep 1, 1994·Hypertension·N BankG A Khan
Aug 26, 1993·Nature·C Randriamampita, R Y Tsien
Jun 1, 1993·Cardiovascular Drugs and Therapy·R FujiwaraS Miyabo
Apr 1, 1993·Kidney International·L D DworkinH D Feiner
Oct 1, 1964·British Journal of Pharmacology and Chemotherapy·J R VANE
Citations
Jul 22, 1999·European Journal of Pharmacology·C F de OliveiraG de Nucci
Jan 4, 2001·Atherosclerosis·J M StulakL O Lerman
May 12, 2000·British Journal of Pharmacology·F Kristek
Jun 2, 1998·Kidney International·H J KlokeJ F Wetzels
Jan 29, 2002·Journal of Cardiovascular Pharmacology·B Jover, A Mimran
Mar 29, 2008·Journal of Veterinary Internal Medicine·R E JepsonJ Elliott
Apr 28, 2005·American Journal of Nephrology·Xiaoyan Zhou, Edward D Frohlich
Dec 18, 1998·Hypertension·R Zatz, C Baylis
Feb 23, 2000·The Journal of Clinical Investigation·J W KnowlesN Maeda
Jul 9, 2003·Kidney International·Harm PetersHans-H Neumayer
Jul 19, 2015·European Journal of Pharmacology·F Ilkay Alp YildirimB Sönmez Uydeş Doğan
Nov 28, 2017·Clinical and Experimental Hypertension : CHE·Hala Salah Abdel Kawy
Mar 19, 2005·Journal of Hypertension·Urmila A ShindeVenkat Gopalakrishnan
Sep 23, 2008·Journal of Hypertension·Teresa M SecciaGian Paolo Rossi
Dec 31, 2019·Oxidative Medicine and Cellular Longevity·M MajzunovaS Cacanyiova